Shandong Xinhua Pharmaceutical Company Limited (XIN) - Total Liabilities
Based on the latest financial reports, Shandong Xinhua Pharmaceutical Company Limited (XIN) has total liabilities worth €3.87 Billion EUR (≈ $4.53 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore XIN cash generation efficiency to assess how effectively this company generates cash.
Shandong Xinhua Pharmaceutical Company Limited - Total Liabilities Trend (2013–2024)
This chart illustrates how Shandong Xinhua Pharmaceutical Company Limited's total liabilities have evolved over time, based on quarterly financial data. Check XIN asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Shandong Xinhua Pharmaceutical Company Limited Competitors by Total Liabilities
The table below lists competitors of Shandong Xinhua Pharmaceutical Company Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ESAF Small Finance Bank
NSE:ESAFSFB
|
India | Rs253.75 Billion |
|
Vente Unique.com
PA:ALVU
|
France | €52.70 Million |
|
Victoria Investama Tbk
JK:VICO
|
Indonesia | Rp29.92 Trillion |
|
Sea Harvest Group Ltd
JSE:SHG
|
South Africa | ZAC5.41 Billion |
|
Digital Daesung Co. Ltd
KQ:068930
|
Korea | ₩165.89 Billion |
|
LK CHEM
KQ:489500
|
Korea | ₩6.53 Billion |
|
Tecogen Inc.
NYSE:TGEN
|
USA | $16.15 Million |
|
AMREP Corporation
NYSE:AXR
|
USA | $4.57 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Shandong Xinhua Pharmaceutical Company Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shandong Xinhua Pharmaceutical Company L market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Xinhua Pharmaceutical Company Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Xinhua Pharmaceutical Company Limited (2013–2024)
The table below shows the annual total liabilities of Shandong Xinhua Pharmaceutical Company Limited from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €3.80 Billion ≈ $4.45 Billion |
+8.31% |
| 2023-12-31 | €3.51 Billion ≈ $4.10 Billion |
-10.34% |
| 2022-12-31 | €3.92 Billion ≈ $4.58 Billion |
+6.37% |
| 2021-12-31 | €3.68 Billion ≈ $4.30 Billion |
-0.56% |
| 2020-12-31 | €3.70 Billion ≈ $4.33 Billion |
+11.31% |
| 2019-12-31 | €3.33 Billion ≈ $3.89 Billion |
+6.60% |
| 2018-12-31 | €3.12 Billion ≈ $3.65 Billion |
+15.79% |
| 2017-12-31 | €2.69 Billion ≈ $3.15 Billion |
+1.92% |
| 2016-12-31 | €2.64 Billion ≈ $3.09 Billion |
+5.40% |
| 2015-12-31 | €2.51 Billion ≈ $2.93 Billion |
+7.49% |
| 2014-12-31 | €2.33 Billion ≈ $2.73 Billion |
+9.74% |
| 2013-12-31 | €2.13 Billion ≈ $2.49 Billion |
-- |
About Shandong Xinhua Pharmaceutical Company Limited
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing service… Read more